Drugs / GIA632
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07431177 | Mar 2026 → Jun 2028 expected | vitiligo | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07220577 | Nov 2025 → May 2027 expected | atopic eczema | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIA632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220577 ↗ |